iBio (NASDAQ:IBIO) Rating Lowered to “Sell” at Wall Street Zen

iBio (NASDAQ:IBIO) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Thursday.

A number of other analysts have also commented on IBIO. Leerink Partnrs raised iBio to a “strong-buy” rating in a report on Friday, October 17th. Weiss Ratings started coverage on iBio in a report on Wednesday, October 15th. They issued a “sell (e+)” rating for the company. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, iBio has an average rating of “Moderate Buy”.

iBio Stock Down 4.7%

iBio stock opened at $1.21 on Thursday. iBio has a 12 month low of $0.56 and a 12 month high of $6.89.

About iBio

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.